Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study.
Alouani E, Mercier M, Flecchia C, Auclin E, Hollebecque A, Mazard T, Turpin A, Pernot S, Cohen R, Dutherage M, Kim S, Sclafani F, Ben-Abdelghani M, Herve C, Aparicio T, De La Fouchardière C, Perkins G, Hautefeuille V, Jaffrelot M, Gallois C, Bongard V, Tougeron D, Taïeb J, Guimbaud R. Alouani E, et al. Among authors: guimbaud r. ESMO Open. 2023 Jun;8(3):101574. doi: 10.1016/j.esmoop.2023.101574. Epub 2023 May 25. ESMO Open. 2023. PMID: 37244250 Free PMC article.
Prognostic score for synchronous metastatic rectal cancer: A real-world study.
Muzellec L, Campion L, Bachet JB, Taieb J, Fremont E, Senellart H, Moreau J, Bouché O, Garric M, Guimbaud R, Greilsamer C, Bodère A, Lièvre A, Girot P, Edeline J, Tougeron D, Bennouna J, Touchefeu Y. Muzellec L, et al. Among authors: guimbaud r. Dig Liver Dis. 2023 Oct;55(10):1411-1416. doi: 10.1016/j.dld.2023.03.004. Epub 2023 Apr 1. Dig Liver Dis. 2023. PMID: 37005173
Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
Marolleau P, Tougeron D, Allignet B, Cohen R, Sefrioui D, Gallet B, Dumont F, Guimbaud R, Alouani E, Passot G, Desolneux G, Ghiringhelli F, Marchal F, Mourthadhoi F, Coriat R, Desgrippes R, Locher C, Goujon G, Des Guetz G, Aparicio T, Paubelle E, Dupré A, de la Fouchardière C. Marolleau P, et al. Among authors: guimbaud r. Int J Cancer. 2023 Oct 1;153(7):1376-1385. doi: 10.1002/ijc.34636. Epub 2023 Jul 5. Int J Cancer. 2023. PMID: 37403609
Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens.
du Rusquec P, Guimbaud R, Le Malicot K, Gornet JM, Nguyen S, Lecomte T, Khemissa-Akouz F, Perrier H, Bouché O, Paoletti X, Le Tourneau C. du Rusquec P, et al. Among authors: guimbaud r. ESMO Open. 2023 Aug;8(4):101616. doi: 10.1016/j.esmoop.2023.101616. Epub 2023 Aug 4. ESMO Open. 2023. PMID: 37542912 Free PMC article. Clinical Trial.
Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma-randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol.
Modesto A, Tougeron D, Tremolières P, Ronchin P, Jouve AD, Leignel DA, Vendrely V, Riou O, Martin-Babau J, Le Sourd S, Mirabel X, Leroy T, Huguet F, Montaigne L, Baumgaertner I, Deslandres M, Moyal E, Seva C, Selves J, Otal P, Pezzella V, Guimbaud R, Filleron T, Quéro L. Modesto A, et al. Among authors: guimbaud r. BMC Cancer. 2023 Oct 12;23(1):966. doi: 10.1186/s12885-023-11227-0. BMC Cancer. 2023. PMID: 37828434 Free PMC article.
Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting.
Saberzadeh-Ardestani B, Jones JC, McWilliams RR, Tougeron D, Halfdanarson TR, Guimbaud R, Hubbard JM, Flecchia C, Shi Q, Alouani E, Sonbol MB, Ticku J, Jin Z, Taieb J, Sinicrope FA. Saberzadeh-Ardestani B, et al. Among authors: guimbaud r. Eur J Cancer. 2024 Jan;196:113433. doi: 10.1016/j.ejca.2023.113433. Epub 2023 Nov 10. Eur J Cancer. 2024. PMID: 37979306
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study.
Flecchia C, Auclin E, Alouani E, Mercier M, Hollebecque A, Turpin A, Mazard T, Pernot S, Dutherage M, Cohen R, Borg C, Hautefeuille V, Sclafani F, Ben-Abdelghani M, Aparicio T, De La Fouchardière C, Herve C, Perkins G, Heinrich K, Kunzmann V, Gallois C, Guimbaud R, Tougeron D, Taieb J. Flecchia C, et al. Among authors: guimbaud r. Br J Cancer. 2024 Feb;130(3):442-449. doi: 10.1038/s41416-023-02524-3. Epub 2023 Dec 15. Br J Cancer. 2024. PMID: 38102227
Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients.
Samalin E, Mazard T, Assenat E, Rouyer M, de la Fouchardière C, Guimbaud R, Smith D, Portales F, Ychou M, Adenis A, Fiess C, Lopez-Crapez E, Thezenas S. Samalin E, et al. Among authors: guimbaud r. Dig Liver Dis. 2024 Jan 16:S1590-8658(24)00001-X. doi: 10.1016/j.dld.2023.12.018. Online ahead of print. Dig Liver Dis. 2024. PMID: 38233313 Free article.
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
Parisi A, Delaunay B, Pinterpe G, Hollebecque A, Blanc JF, Bouattour M, Assenat E, Ben Abdelghani M, Sarabi M, Niger M, Vivaldi C, Mandalà M, Palloni A, Bensi M, Garattini SK, Tougeron D, Combe P, Salati M, Rimini M, Cella CA, Tucci M, Diana A, Mori E, Longarini R, Artru P, Roth G, Evesque L, Vienne A, Turpin A, Hiret S, Bourgeois V, Herve C, Paulon R, Stacoffe M, Malka D, Neuzillet C, Edeline J, Lievre A, Guimbaud R, Chapda MCP, Rimassa L, Giampieri R, Valle J, Berardi R, Fares N. Parisi A, et al. Among authors: guimbaud r. Eur J Cancer. 2024 Mar;200:113587. doi: 10.1016/j.ejca.2024.113587. Epub 2024 Feb 6. Eur J Cancer. 2024. PMID: 38340384 Free article.
A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.
Moreau M, Alouani E, Flecchia C, Falcoz A, Gallois C, Auclin E, André T, Cohen R, Hollebecque A, Turpin A, Pernot S, Masson T, Di Fiore F, Dutherge M, Mazard T, Hautefeuille V, Van Laethem JL, De la Fouchardière C, Perkins G, Ben-Abdelghani M, Sclafani F, Aparicio T, Kim S, Vernerey D, Taieb J, Guimbaud R, Tougeron D. Moreau M, et al. Among authors: guimbaud r. Eur J Cancer. 2024 May;202:114033. doi: 10.1016/j.ejca.2024.114033. Epub 2024 Mar 21. Eur J Cancer. 2024. PMID: 38537314 Free article. Clinical Trial.
212 results